IMVT

Immunovant Inc

NASDAQ: IMVT · HEALTHCARE · BIOTECHNOLOGY

$37.29

+0.30% today

Updated 2026-09-22

Market cap

$7.68B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.81

Dividend yield

—

52W range

$15 – $45

Volume

1.1M

Market cap

$7.68B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.81

Dividend yield

—

52W range

$15 – $45

Volume

1.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.3

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

1.6

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →253 stocks currently score above 75

Price targets

Analyst target

$48.88

+31.08%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy10 Buy4 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 2/9 — weak financial health

- Altman Z 1.64 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-124.41M

Key financials

Revenue Net Income Free Cash Flow

Metric	2023	2024	2025	2026	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$7.09M
Net income	$-210.96M	$-259.34M	$-413.84M	$-505.61M	$-153.22M
EPS	—	—	—	—	$-2.81
Free cash flow	$-188.39M	$-214.59M	$-376.63M	$-407.32M	$-124.41M
Profit margin	—	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-08-28	PANDE, ATUL	Sale	1,500	—
2026-08-28	PANDE, ATUL	Buy	1,500	$8.43
2026-08-20	GLORIA, MELANIE	Sale	3,056	$44.16

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
IMVT	$7.68B	23	4.3	3.0	5.0	6.3	—	Avoid
LLY	$994.92B	76	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$640.02B	59	4.7	8.5	3.7	5.5	—	Buy
ABBV	$454.36B	73	6.7	8.5	4.0	5.0	-73.51%	Strong Buy
MRK	$355.10B	36	4.0	4.5	2.0	5.0	-77.20%	Hold
UNH	$340.27B	62	7.3	5.5	4.7	5.5	-15.43%	Buy

Smart narrative

Immunovant Inc trades at $37.29. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 1.64, it sits in the distress.

Frequently asked questions

What is Immunovant Inc's stock price?

Immunovant Inc (IMVT) trades at $37.29.

Is Immunovant Inc overvalued?

Immunovant Inc carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Immunovant Inc (IMVT)?

The 12-month analyst consensus target is $48.88, about 31.1% above the current $37.29. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Immunovant Inc's Altman Z-Score is 1.64, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

immunovant.com

Quick metrics

P/S ratio—

ROE-59.30%

Beta0.81

50D MA$40.11

200D MA$31.28

Shares out0.21B

Float0.09B

Short ratio—

Avg volume1.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

IMVT vs LLY →IMVT vs JNJ →IMVT vs ABBV →Stock screener →